Stories by Trevor Hallam

Trevor Hallam, Ph.D., is the Chief Scientific Officer of Sutro Biopharma, a company developing a new generation of antibody-drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies developed using the company's cell-free protein synthesis technology. Sutro has formed multiple partnerships with big pharma surrounding this technology, including Celgene, Pfizer and Sanofi Pasteur, and has established a Good Manufacturing Practice (cGMP) facility for the production of clinical supplies of materials using its biochemical protein synthesis platform. Dr. Hallam has more than 25 years of experience in drug discovery and development, previously holding senior management positions at Palatin Technologies, AstraZeneca, Roche and Glaxo SmithKline. Dr. Hallam received post-doctoral training at the Physiological Laboratory, University of Cambridge, UK, after a doctorate in biochemistry from King's College, University of London and bachelor's degree in biochemistry from the University of Leeds.